Harpoon Therapeutics, Inc. (NASDAQ:HARP) major shareholder Impact Fund (Cayman) Oncology sold 328,519 shares of the business’s stock in a transaction dated Tuesday, May 4th. The shares were sold at an average price of $22.48, for a total value of $7,385,107.12. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Impact Fund (Cayman) Oncology also recently made the following trade(s):
- On Thursday, April 29th, Impact Fund (Cayman) Oncology sold 130,143 shares of Harpoon Therapeutics stock. The shares were sold at an average price of $21.99, for a total transaction of $2,861,844.57.
Shares of NASDAQ HARP traded down $0.05 during midday trading on Tuesday, reaching $23.20. The stock had a trading volume of 398,285 shares, compared to its average volume of 277,394. The company’s 50 day moving average price is $20.69 and its 200 day moving average price is $18.31. Harpoon Therapeutics, Inc. has a twelve month low of $10.55 and a twelve month high of $25.24. The firm has a market cap of $751.94 million, a price-to-earnings ratio of -10.89 and a beta of 0.87.
A number of analysts have recently weighed in on the stock. SVB Leerink cut their price target on shares of Harpoon Therapeutics from $31.00 to $29.00 and set an “outperform” rating for the company in a report on Wednesday, March 17th. Robert W. Baird restated a “buy” rating and set a $35.00 target price on shares of Harpoon Therapeutics in a research note on Monday, March 22nd. Finally, Zacks Investment Research downgraded shares of Harpoon Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 15th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Harpoon Therapeutics presently has an average rating of “Buy” and an average target price of $30.78.
Large investors have recently bought and sold shares of the company. US Bancorp DE raised its holdings in shares of Harpoon Therapeutics by 42.1% in the 4th quarter. US Bancorp DE now owns 1,705 shares of the company’s stock worth $28,000 after acquiring an additional 505 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Harpoon Therapeutics during the 3rd quarter worth approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Harpoon Therapeutics during the 1st quarter worth approximately $50,000. Pura Vida Investments LLC purchased a new stake in shares of Harpoon Therapeutics in the fourth quarter worth approximately $169,000. Finally, Citigroup Inc. lifted its holdings in shares of Harpoon Therapeutics by 31.6% in the fourth quarter. Citigroup Inc. now owns 11,988 shares of the company’s stock valued at $199,000 after purchasing an additional 2,880 shares in the last quarter. 79.03% of the stock is owned by institutional investors.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer.
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.